endocrine and chemotherapy
Correlation of the anxiety caused by postoperative chemotherapy with endocrine disorder and immune response in patients with colorectal cancer
... during chemotherapy and then form bad state of ...during chemotherapy, and some patients even show decline in compliance and quit the treatment, which is not conducive to obtaining the expected curative ...
5
Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone.
... of endocrine therapy but the question who will benefit from adjuvant chemotherapy is more ...without chemotherapy and proportional reductions were largely independent by clin- ico-pathological ...
10
Lapatinib plus chemotherapy or endocrine therapy (CET) versus CET alone in the treatment of HER-2-overexpressing locally advanced or metastatic breast cancer: systematic review and meta-analysis
... On January 29, 2010, the FDA granted accelerated approval to lapatinib for use in combination with endocrine therapy (letrozole) for the treatment of postmenopausal women with HER-2 + metastatic breast cancer and ...
10
Neoadjuvant Endocrine Therapy in Breast Cancer Upregulates the Cytotoxic Drug Pump ABCG2/BCRP, and May Lead to Resistance to Subsequent Chemotherapy
... following endocrine treatment, we examined published microarray mRNA expression datasets of matched samples from breast cancer patients, taken before and after aromatase inhibitor ...
19
Clinical outcomes among HR+/HER2− metastatic breast cancer patients with multiple metastatic sites: a chart review study in the US
... are in late-stage clinical development, including mam- malian target of rapamycin (mTOR) inhibitors (e.g., everolimus), cyclin dependent kinase (CDK)-4/6 inhibi- tors (e.g., palbociclib), and phosphoinositide 3-kinase ...
9
Identifying patients at high risk of breast cancer recurrence: strategies to improve patient outcomes
... Avoid ChemoTherapy (MINDACT) trial is the first major prospective validation of molecular ...then chemotherapy will be withheld; if both classify as high risk, then adjuvant chemotherapy will be ...
7
Case Report A case of breast primary neuroendocrine carcinoma treated with neoadjuvant endocrine therapy
... Neoadjuvant endocrine therapy that is similar to neoadjuvant chemotherapy can make the breast cancer sensitive to endocrine therapy to achieve the purpose of down staging the pri- mary tumor and ...
5
Multiple endocrine neoplasia type 1
... Multiple Endocrine Neoplasia type 1 (MEN1) is a rare autosomal dominant hereditary cancer syndrome presented mostly by tumours of the parathyroids, endocrine pancreas and anterior pituitary, and ...
9
Long term hazard of recurrence in HER2+ breast cancer patients untreated with anti HER2 therapy
... From previous data in HER2-untested cohorts [7-9,11,12], reporting that HR expression exhibits time-dependent nonproportional hazard effects on prognosis [8,9], it was unclear whether these effects would also be present ...
7
Role of neo-adjuvant hormonal therapy in the treatment of breast cancer: a review of clinical trials
... included 451 postmenopausal women with an ER-positive primary breast cancer. These patients were randomized to receive preoperative anastrozole (n = 228) versus tamoxifen (n = 223) for a duration of 12 weeks followed by ...
12
Efficient development and usability testing of decision support interventions for older women with breast cancer
... Patients facing the decision only DESI-S, Primary endocrine therapy/surgery+endocrine therapy DESI; DESI-C, chemotherapy DESI; Bo, booklet; Br, brief decision aid; SUT, Primary endocrine[r] ...
37
Cnossen, Jitske (2011): Overall survival in metastatic breast cancer patients: a single-centre analysis (2000-2005). Dissertation, LMU München: Medizinische Fakultät
... any chemotherapy treatment with an improved ...with endocrine therapy, had bone metastasis and were treated with bisphosphonates or had a loco-regional treatment ...
87
Efficient development and usability testing of decision support interventions for older women with breast cancer
... Two DESIs for older women with breast cancer have been successfully developed for two different treatment choices (primary endocrine therapy / surgery+endocrine therapy and chemotherapy / no ...
13
C myc, not HER 2/neu, can predict recurrence and mortality of patients with node negative breast cancer
... as chemotherapy (cyclophosphamide, methotrexate, 5- fluorouracil; fluorouracil, epirubicin, cyclophosphamide) and endocrine therapy (tamoxifen), no significant differences were identified in ...
7
Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer
... negative advanced BC after disease progression following endocrine therapy and prior chemotherapy. At the same time, following the positive results of the MONARCH-2 trial 45 , abemaciclib also received ...
26
Haematological profile of Channastriatus exposed to sublethal concentrations of endocrine disruptor chemical Triclosan
... Endocrine disruptors come from a wide range of sources, such as pesticides, plastics, pharmaceuticals, household chemicals, and industrial chemicals. They alter the hormonal functions, which prevent normal ...
12
Comparative study of immunocytochemical patterns of somatotrophs, mammotrophs, and mammosomatotrophs in the porcine anterior pituitary
... The anterior pituitary consists of three regions (pars distalis, pars intermedia, and pars tuberalis) within the sella turcica and lies outside blood-brain barrier. It does not belong to nerve terminals and forms of a ...
174
Haematological profile of Channa striatus exposed to sublethal concentrations of endocrine disruptor chemical Triclosan
... Endocrine disruptors come from a wide range of sources, such as pesticides, plastics, pharmaceuticals, household chemicals, and industrial chemicals. They alter the hormonal functions, which prevent normal ...
12
Cushing syndrome: uncovering Carney complex due to novel PRKAR1A mutation
... PPNAD can occur as part of CNC, a rare multiple neoplasia syndrome characterized by spotty skin pigmentation, myxomas and endocrine tumors. The diagnosis of CNC can be made based on major clinical manifestations, ...
5
Bicaudal C1 promotes pancreatic NEUROG3+ endocrine progenitor differentiation and ductal morphogenesis
... 4. Endocrine cell decrease is caused by endocrine progenitor generation ...in endocrine progenitor ...+ endocrine progenitors toward hormone + endocrine ...
14